BTIG Maintains Buy on Climb Bio, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 74.8%

Neg 0% Neu 0% Pos 74.8%

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.

Comments

No comments yet. Be the first!